drugset / Trial / NCT01572025

Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging

NCT01572025

Phase 3 Completed 60 enrolled University of Nottingham
RandomizedParallel-groupQuadruple-blindTreatment

Summary

* To test the hypothesis that supplementation of DHEA for at least twelve weeks prior to and during ovarian stimulation increases oocyte quantity (number of oocytes retrieved) and oocyte quality (clinical pregnancy rates and molecular markers) following IVF and IVF/ICSI treatment. * To evaluate the feasibility of conducting a large multicentre trial

Timeline

Start
2012-05
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dehydroepiandrosterone Other / unclassified 75 mg